Show simple item record

dc.contributor.authorMatoori, Sen_US
dc.contributor.authorThian, Yen_US
dc.contributor.authorKoh, D-Men_US
dc.contributor.authorSohaib, Aen_US
dc.contributor.authorLarkin, Jen_US
dc.contributor.authorPickering, Len_US
dc.contributor.authorGutzeit, Aen_US
dc.date.accessioned2017-07-19T15:39:11Z
dc.date.issued2017-08en_US
dc.identifier.citationTranslational oncology, 2017, 10 (4), pp. 679 - 685en_US
dc.identifier.issn1936-5233en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/727
dc.identifier.eissn1936-5233en_US
dc.identifier.doi10.1016/j.tranon.2017.06.001en_US
dc.description.abstractThe first-line therapy in metastatic renal cell carcinoma (mRCC), sunitinib, exhibits an objective response rate of approximately 30%. Therapeutic alternatives such as other tyrosine kinase inhibitors, VEGF inhibitors, or mTOR inhibitors emphasize the clinical need to predict the patient's response to sunitinib therapy before treatment initiation. In this study, we evaluated the prognostic value of pretreatment portal venous phase contrast-enhanced computed tomography (CECT) mean tumor density on overall survival (OS), progression-free survival (PFS), and tumor growth in 63 sunitinib-treated mRCC patients. Higher pretreatment CECT tumor density was associated with longer PFS and OS [hazard ratio (HR)=0.968, P=.002, and HR=0.956, P=.001, respectively], and CECT density was inversely correlated with tumor growth (P=.010). Receiver operating characteristic analysis identified two CECT density cut-off values (63.67 HU, sensitivity 0.704, specificity 0.694; and 68.67 HU, sensitivity 0.593, specificity 0.806) which yielded subpopulations with significantly different PFS and OS (P<.001). Pretreatment CECT is therefore a promising noninvasive strategy for response prediction in sunitinib-treated mRCC patients, identifying patients who will derive maximum therapeutic benefit.en_US
dc.formatPrint-Electronicen_US
dc.format.extent679 - 685en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.titleContrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-06-05en_US
rioxxterms.versionofrecord10.1016/j.tranon.2017.06.001en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
rioxxterms.licenseref.startdate2017-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfTranslational oncologyen_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume10en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorKoh, Dow-Muen_US
dc.contributor.icrauthorLarkin, Jamesen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/